Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Novel Carbazole-Piperazine Hybrid Small Molecule Induces Apoptosis by Targeting BCL-2 and Inhibits Tumor Progression in Lung Adenocarcinoma in Vitro and Xenograft Mice Model.
|
31450709 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Cancers often overexpress anti-apoptotic Bcl-2 proteins for cell death evasion, a recognized hallmark of cancer progression.
|
31595181 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
However, cancer cells frequently show upregulation of pro-survival Bcl-2 proteins and sequester activated pro-apoptotic BH3-only proteins driven by diverse cytotoxic stresses, resulting in tumor progression and chemoresistance.
|
31129454 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Notably, in a mouse model of DHL bearing primary tumor cells derived from lymphoma patients, combined treatment with XPO1 and BCL2 inhibitors blocks tumor progression, prevents brain metastasis, and extends host survival.
|
31752970 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The combination of DOX and KIR may promote therapeutic efficacy, at which the anti-apoptotic effect of the tumour cells was inhibited (by downregulating Bcl-2 and upregulating Bax) and the tumour progression-related inflammatory factors, such as tumour necrosis factor α (TNF-α) and interleukin-6 (IL-6) were downregulated.
|
30880468 |
2019 |
Tumor Progression
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression.
|
31103719 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These findings revealed a novel mechanism of PPAR<i>α</i>/Bcl2/autophagy pathway suppressed tumor progression and enhanced chemotherapy sensitivity, which is a potential drug target for cancer treatment.
|
30519260 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We showed that CXCL8 secreted by tumor cells at the invasion front were able to promote migration through angiogenesis by upregulating VEGFA and invasion via the AKT/GSK3β/β-catenin/MMP7 pathway by upregulating BCL-2 confirming the key role of CXCL8 during tumor progression.
|
29679563 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Due to its predominant role in cancer progression, the Bcl-2 family proteins act as attractive therapeutic targets.
|
28793831 |
2018 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The overexpression of mortalin and Bcl-2 and/or the low expression of Bax are implicated in the anti-apoptotic effect and tumor progression of ICC.
|
29434920 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We propose that Bcl-2 proteins and complex-I are potential targets for preventing tumor progression and the malignant actions of radiotherapy.
|
29596889 |
2018 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
BC094916 overexpression suppressed Creb1 and Bcl2 transcription to induce cell apoptosis, which suppressed SP 2/0 proliferation and xenograft tumor progression.
|
30220882 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The mitochondrial apoptosis pathway is controlled by an interaction of multiple BCL-2 family proteins, and plays a key role in tumour progression and therapy responses.
|
27663504 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of anti-apoptotic Bcl-2 family proteins contributes to cancer progression and confers resistance to chemotherapy.
|
28594323 |
2017 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Over-expression of MCL-1 has been closely related to tumor progression as well as to resistance, not only to traditional chemotherapies but also to targeted therapeutics including BCL-2 inhibitors such as ABT-263.
|
27744724 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our studies not only define the essential role of Mcl-1 in chemoresistance, but also for the first time link a key pro-survival Bcl-2 family member with the NOX protein family, both of which have significant ramifications in cancer progression.
|
28423654 |
2017 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Studies have shown that Bcl-2 expression in human osteosarcoma (OS) cells plays a significant role in tumor progression; however, its effects on OS cell apoptosis are still unknown.
|
28849162 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mechanistic investigations reveal that a miR-197-mediated CKS1B/STAT3 axis exerts tumor progression regulated by various oncogenic genes (Bcl-2, c-Myc, and cyclin D1), and PD-L1 is a putative biomarker of this axis.
|
25597412 |
2015 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment.
|
25827952 |
2015 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
B-cell lymphoma-extra large (Bcl-xL), an important member of anti-apoptotic Bcl-2 family, is involved in tumor progression and development.
|
25683634 |
2015 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
No significant risk for developing tumor progression was associated with Ki-67, p53, Bax, Bcl-2, VEGFR-1, VEGFR-2, or VEGF-A expression.
|
25109698 |
2014 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In SCRT, long break in the treatment should be avoided because correlation between Ki-67, KU70, and BCL-2 expressions and pTNM after RT might indicate tumor progression.
|
24756926 |
2014 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Moreover, the enhanced expression and/or activities of some drug resistance-associated molecules such as Bcl-2, Akt/molecular target of rapamycin (mTOR), nuclear factor-kappaB (NF-κB), hypoxia-inducible factors (HIFs), macrophage inhibitory cytokine-1 (MIC-1) and ATP-binding cassette (ABC) multidrug transporters frequently occur in cancer cells during cancer progression and metastases.
|
23994756 |
2014 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Deregulation of apoptosis is one of the important features of AML and to understand the molecular mechanism underlying apoptosis and its contribution to tumor progression, this study aimed to evaluate anti-apoptotic Bcl2 protein expression in AML and correlate with FLT3 parameters for their role in prognosis of disease.Bcl2 and FLT3 protein expression was quantified by flow cytometry on leukemic blasts in total 174 de novo AML, myelodysplastic syndrome (MDS) and aplastic anemia patients.
|
23906301 |
2013 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, the expression of integrins and Bcl-2 in LCs had a tendency to correlate with the clinical stage of cancer progression, including lymph node metastasis.
|
23108890 |
2013 |